Trial Profile
Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Aug 2023
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 02 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 08 Feb 2023 Planned End Date changed from 1 Jun 2022 to 18 Oct 2028.
- 20 Sep 2021 Planned End Date changed from 1 Jun 2021 to 1 Jun 2022.